Study S001599

An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01960179
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 361
Start: 2013-11
Primary completion: 2015-03
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:lixisenatide AVE0010
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1134-2695

Registered primary outcomes

Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data. [from baseline to 24 weeks and 52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.